New Tracers PET in Head and Neck Squamous Cell Carcinoma

Tony J C Wang; Yusuf Menda; Simon K Cheng; Cheng-Chia Wu; Nancy Y Lee

doi:10.1016/j.cpet.2012.06.009

New Tracers PET in Head and Neck Squamous Cell Carcinoma

PET Clin. 2012 Oct;7(4):431-41. doi: 10.1016/j.cpet.2012.06.009.

Authors

Tony J C Wang¹, Yusuf Menda², Simon K Cheng¹, Cheng-Chia Wu¹, Nancy Y Lee³

Affiliations

¹ Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, 622 West 168th Street, New York, NY 10032, USA.
² Department of Radiology, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA.
³ Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: leen2@mskcc.org.

PMID: 27157649
DOI: 10.1016/j.cpet.2012.06.009

Abstract

PET is commonly used in the evaluation and posttreatment management of head and neck squamous cell carcinoma. Although [(18)F]fluorodeoxyglucose is the most commonly used radiopharmaceutical, many other radiopharmaceuticals are under investigation to assess particular biologic characteristics such as hypoxia and tumor repopulation. In this review, the authors discuss new PET tracers that allow the biologic profiling of head and neck squamous cell carcinomas, including [(18)F]fluoromisonidazole, [(18)F]fluorothymidine, [(18)F]fluoromethyltyrosine, and epidermal growth factor receptor biomarkers.